Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer
Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify new treatment regimens with better response rates
and to find out if the combination of cisplatin and sorafenib followed by paclitaxel and
sorafenib can shrink the size of your breast tumor and allow you to preserve your breast.
Sorafenib is a newer drug that targets blood vessel formation and may help the chemotherapy
work better. Additionally, by receiving chemotherapy before surgery, we will be able to
determine if your cancer is responsive to chemotherapy.